Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kylo-12 in Healthy Subjects with Elevated Triglycerides
NCT06783881Phase 1Active, not recruiting
- Sponsor
- Kylonova Biopharma
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertriglyceridemia comparing Kylo-12 with Placebo (2 arms). Primary endpoint: Incidence of adverse events at 24 weeks. Started Mar 2025; status: active, not recruiting.
02
Drugs
kylo-12
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT06783881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06783881.